시장보고서
상품코드
1293850

비알코올성 지방간염(NASH) 치료제 시장 - 성장, 향후 전망, 경쟁 분석(2023-2031년)

Nonalcoholic Steatohepatitis (NASH) Treatment Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031

발행일: | 리서치사: Acute Market Reports | 페이지 정보: 영문 120 Pages | 배송안내 : 1-2일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

비알코올성 지방간염(NASH) 치료제 시장은 2031년까지 38% 성장할 것으로 예상됩니다. 비알코올성 지방간염(NASH)은 알코올 중독이 아닌 환자에서 발생하는 질환으로, 주로 알코올성 간염과 진단적으로 구분할 수 없을 정도로 간 손상을 일으키기 때문에 '지방간'이라고도 불리며, NASH 환자의 주요 위험요인은 비만, 내당능 이상, 이상지질혈증입니다. 이 질병의 진단에 직면한 도전은 주로 비만과 대사 증후군에서 인슐린 저항성과 관련된 병인에 대한 불충분한 이해에 기인합니다. 시장 전문가에 따르면 대부분의 환자는 무증상이며 NASH와 관련된 검사 소견은 주로 아미노 전이 효소 수치 상승입니다. 그러나 NASH 진단에서 생검은 중요한 역할을 합니다. 미국 간 재단에 따르면 NASH는 미국 간 이식의 세 번째 원인이며, 데이터베이스에 따르면 일반 인구의 12% 이상이 NASH를 앓고 있으며, 약 2.7%가 간 섬유화가 진행 중이라고 합니다. NASH 치료에서 체중감량은 성인에서 광범위하게 연구되어 왔으며, 생화학적 결과뿐만 아니라 조직학적 개선도 입증되었습니다.

Cleveland Clinic에 따르면, 식이 탄수화물, 특히 식이 과당을 줄이는 것이 가장 효과적이며 과체중 환자의 지질 프로필을 개선하는 것으로 밝혀졌습니다. 세로토닌 재흡수 억제제인 시부트라민과 지방 흡수를 억제하는 올리스타트 등 몇 가지 약물이 연구되고 있습니다. 이들 약물은 모두 간 효소 수치와 지방간 초음파 검사에서 지방간 징후를 개선하는 것으로 나타났습니다. 카나비노이드-1 길항제인 리모나반트의 메타분석 결과, 부작용이 증가하여 현재 NAFLD에는 권장하지 않고 있습니다. 인슐린 감수성 강화제로는 퍼옥시좀 증식제 활성화 수용체 γ(PPARg) 작용제(티오글리타존)가 지방간 대체 마커로 작용하여 간과 근육에서 증식하는 지방세포로 트리글리세리드 재분배를 촉진하고 인슐린 저항성을 개선할 수 있을 것으로 예측됩니다. 최근 발표된 '칠레 소화기학회'와 '칠레 간학회'의 전문가 총평에 따르면, 피오글리타존과 비타민 E의 병용은 생검으로 입증된 NASH 환자를 위한 약리학적 옵션으로 입증되었지만, 장기적인 안전성과 효과에 대한 증거는 부족합니다. 또한, 미국 간학회 가이드라인에 따르면 피오글리타존은 NASH 치료제로서의 잠재력을 가지고 있습니다.

NASH 치료제의 가장 큰 시장은 북미, 그 다음이 유럽인 것으로 확인됐습니다. 북미에서는 비만과 당뇨병 발병률의 증가가 NASH 치료제 시장을 이끄는 주요 요인으로, 클리블랜드 클리닉(Cleveland Clinic)에 따르면 미국 내 과체중 유병률이 65% 이상에 달하며 현재 미국 성인 인구의 30% 이상이 비만인 것으로 나타났습니다. 남성, 노인(40-70세), 대사 증후군(특히 당뇨병과 복부 비만)의 구성요소를 가진 사람 일수록 유병률이 높습니다. 소아 비만과 비알콜성 지방간 질환(NAFLD)의 유병률은 비슷하며, NAFLD는 모든 인종에서 관찰되며, 백인과 아프리카계 미국인에 비해 히스패닉에서 가장 높은 유병률을 보이는 아시아태평양이 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예상됩니다.

목차

제1장 서문

  • 보고서 내용
    • 보고서 목적
    • 대상 독자
    • 주요 제공 상품
  • 시장 세분화
  • 조사 방법
    • 단계Ⅰ - 2차 조사
    • 단계Ⅱ - 1차 조사
    • 단계Ⅲ - 전문가 패널 리뷰
    • 가정
    • 채용한 접근법

제2장 주요 요약

제3장 비알코올성 지방간염(NASH) 치료제 시장 : 경쟁 분석

  • 주요 벤더의 시장에서의 포지셔닝
  • 벤더가 채용하는 전략
  • 주요 산업 전략
  • 계층 분석 : 2022 vs 2031

제4장 비알코올성 지방간염(NASH) 치료제 시장 : 거시적 분석과 시장 역학

  • 서론
  • 세계의 비알코올성 지방간염(NASH) 치료제 시장 금액
  • 시장 역학
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
    • 주요 과제
    • 주요 기회
  • 성장 촉진요인과 억제요인의 영향 분석
  • See Saw 분석

제5장 비알코올성 지방간염(NASH) 치료제 시장 : 약제 종류별

  • 시장 개요
  • 성장·매출 분석 : 2022 vs 2031
  • 시장 세분화
    • 비타민 E와 피오글리타존
    • 오베티콜산(OCA)
    • 라니피브라노르
    • 세마글루타이드
    • 레스메티롬
    • 아람콜
    • 세니크리비록
    • 기타

제6장 비알코올성 지방간염(NASH) 치료제 시장 : 최종 용도별

  • 시장 개요
  • 성장·매출 분석 : 2022 vs 2031
  • 시장 세분화
    • 병원 약국
    • 소매점 및 전문 약국
    • 기타

제7장 북미의 비알코올성 지방간염(NASH) 치료제 시장

  • 시장 개요
  • 비알코올성 지방간염(NASH) 치료제 시장 : 약제 종류별
  • 비알코올성 지방간염(NASH) 치료제 시장 : 최종 용도별
  • 비알코올성 지방간염(NASH) 치료제 시장 : 지역별
    • 북미
      • 미국
      • 캐나다
      • 기타 북미

제8장 영국과 유럽연합의 비알코올성 지방간염(NASH) 치료제 시장

  • 시장 개요
  • 비알코올성 지방간염(NASH) 치료제 시장 : 약제 종류별
  • 비알코올성 지방간염(NASH) 치료제 시장 : 최종 용도별
  • 비알코올성 지방간염(NASH) 치료제 시장 : 지역별
    • 영국과 유럽연합
      • 영국
      • 독일
      • 스페인
      • 이탈리아
      • 프랑스
      • 기타 유럽

제9장 아시아태평양의 비알코올성 지방간염(NASH) 치료제 시장

  • 시장 개요
  • 비알코올성 지방간염(NASH) 치료제 시장 : 약제 종류별
  • 비알코올성 지방간염(NASH) 치료제 시장 : 최종 용도별
  • 비알코올성 지방간염(NASH) 치료제 시장 : 지역별
    • 아시아태평양
      • 중국
      • 일본
      • 인도
      • 호주
      • 한국
      • 기타 아시아태평양

제10장 라틴아메리카의 비알코올성 지방간염(NASH) 치료제 시장

  • 시장 개요
  • 비알코올성 지방간염(NASH) 치료제 시장 : 약제 종류별
  • 비알코올성 지방간염(NASH) 치료제 시장 : 최종 용도별
  • 비알코올성 지방간염(NASH) 치료제 시장 : 지역별
    • 라틴아메리카
      • 브라질
      • 멕시코
      • 기타 라틴아메리카

제11장 중동 및 아프리카의 비알코올성 지방간염(NASH) 치료제 시장

  • 시장 개요
  • 비알코올성 지방간염(NASH) 치료제 시장 : 약제 종류별
  • 비알코올성 지방간염(NASH) 치료제 시장 : 최종 용도별
  • 비알코올성 지방간염(NASH) 치료제 시장 : 지역별
    • 중동 및 아프리카
      • GCC
      • 아프리카
      • 기타 중동 및 아프리카

제12장 기업 개요

  • Intercept Pharmaceuticals
  • Galmed Pharmaceuticals
  • Inventiva Pharma
  • AbbVie Inc.
  • Galectin Therapeutics Inc.
  • Madrigal Pharmaceuticals
  • NGM Biopharmaceuticals Inc.
  • Novo Nordisk A/S
  • Bristol Myers Squibb
  • Gilead Sciences Inc.
ksm 23.07.05

Nonalcoholic Steatohepatitis (NASH) Treatment Market is Expected to Grow at 38% by 2031. Nonalcoholic steatohepatitis (NASH) is also known as 'fatty liver' a disorder that develops in patients who are not alcoholic; mainly causes liver damage that is diagnostically indistinguishable from alcoholic hepatitis. The key risk factors observed in patients suffering from NASH are obesity, glucose intolerance, and dyslipidemia. The challenges that are faced in the diagnosis of the disease are mainly due to poor understanding of pathogenesis linked to insulin resistance especially in obesity or metabolic syndrome. Market experts suggest that most of the patients are asymptomatic and laboratory findings related with NASH mainly include elevations in aminotransferase levels. However, in diagnosis of NASH biopsy pays key role in diagnosis. According to American Liver Foundation, NASH is the third leading cause of liver transplant in the U.S.; database suggests more than 12% of the general population has NASH and approximately 2.7% have advanced liver fibrosis due to the disease. NASH comprises treatment of obesity, insulin-sensitizing agents, lipid-lowering agents, antioxidants, and hepatoprotective therapy. In NASH treatment weight reduction has been widely studied in adults and has shown improvement not only the biochemical results but also the histology.

According to Cleveland Clinic, the reduction of dietary carbohydrates, in particular dietary fructose, is the most beneficial and has been found to improve the lipid profile in overweight patients. Several drugs have been studied, including sibutramine, a serotonin reuptake inhibitor, and orlistat, which reduce fat absorption. Both of these have been shown to improve liver enzyme levels and sonographic signs of fatty liver. A meta-analysis of rimonabant, a cannabinoid-1-antagonist, showed that it is associated with increased adverse events and currently it cannot be recommended for NAFLD. In case of insulin-sensitizing agents, peroxisome proliferator-activated receptor gamma (PPARg) agonists (thioglitazones) have projected improvement in insulin resistance, by acting as surrogate marker of fatty liver, and promoting redistribution of triglycerides from the liver and muscle into proliferating adipocytes. According to a recently published review article that was conducted by an expert panel from the "Chilean Gastroenterological Society" and the "Chilean Hepatology Association" suggested that pioglitazone along with vitamin E is a proven pharmacological choice for patients with biopsy-proven NASH, however evidence on its long-term safety and efficacy is lacking. Moreover, the guidelines of the American Association for the Study of Liver Diseases indicate pioglitazone as a possible therapeutic drug for the treatment of NASH.

North America was observed as the largest market for NASH treatment followed by Europe. In North America, the rising prevalence of obesity, and the increasing incidence of diabetes are the key factors assisting the NASH treatment market. According to Cleveland Clinic, The prevalence of overweight persons in the US has risen to more than 65%, and obesity is now present in more than 30% of the adult US population. The prevalence is increased in men, older individuals (those aged 40-70 years), and those with components of the metabolic syndrome especially diabetes and abdominal obesity. The prevalence of childhood obesity and non-alcoholic fatty liver disease (NAFLD) is at similar levels. NAFLD has been observed in all ethnic groups with the highest prevalence seen in Hispanics compared with Caucasians and African Americans Asia Pacific was anticipated to grow at the fastest CAGR during the forecast period.

Key Players Identified for Non-Alcoholic Steatohepatitis (NASH) Treatment Market Include but are Not Limited to:

  • Intercept Pharmaceuticals
  • Galmed Pharmaceuticals
  • Inventiva Pharma
  • AbbVie Inc.
  • Galectin Therapeutics Inc.
  • Madrigal Pharmaceuticals
  • NGM Biopharmaceuticals Inc.
  • Novo Nordisk A/S
  • Bristol Myers Squibb
  • Gilead Sciences Inc.

Historical & Forecast Period

This study report represents an analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review.A key data point that enables the estimation of Nonalcoholic Steatohepatitis (NASH) Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Nonalcoholic Steatohepatitis (NASH) Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approaches for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

Segmentation

Drug Type

  • Vitamin E and Pioglitazone
  • Obeticholic Acid (OCA)
  • Lanifibranor
  • Semaglutide
  • Resmetirom
  • Aramchol
  • Cenicriviroc
  • Others

End-use

  • Hospital Pharmacies
  • Retail & Specialty Pharmacies
  • Others

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Nonalcoholic Steatohepatitis (NASH) Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Nonalcoholic Steatohepatitis (NASH) Treatment market?
  • Which is the largest regional market for Nonalcoholic Steatohepatitis (NASH) Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Nonalcoholic Steatohepatitis (NASH) Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Nonalcoholic Steatohepatitis (NASH) Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market
  • 2.2. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Drug Type, 2022 (US$ Million)
  • 2.3. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By End-use, 2022 (US$ Million)
  • 2.4. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Geography, 2022 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2022

3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: Competitive Analysis

  • 3.1. Market Positioning of Key Nonalcoholic Steatohepatitis (NASH) Treatment Market Vendors
  • 3.2. Strategies Adopted by Nonalcoholic Steatohepatitis (NASH) Treatment Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Nonalcoholic Steatohepatitis (NASH) Treatment Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Vitamin E and Pioglitazone
    • 5.3.2. Obeticholic Acid (OCA)
    • 5.3.3. Lanifibranor
    • 5.3.4. Semaglutide
    • 5.3.5. Resmetirom
    • 5.3.6. Aramchol
    • 5.3.7. Cenicriviroc
    • 5.3.8. Others

6. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail & Specialty Pharmacies
    • 6.3.3. Others

7. North America Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
  • 7.3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
  • 7.4.Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Region, 2021-2031, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 7.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 7.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 7.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)

8. UK and European Union Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
  • 8.3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
  • 8.4.Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Region, 2021-2031, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 8.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 8.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 8.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 8.4.1.4.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 8.4.1.5.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 8.4.1.6.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)

9. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
  • 9.3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
  • 9.4.Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Region, 2021-2031, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 9.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 9.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 9.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 9.4.1.4.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 9.4.1.5.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 9.4.1.6.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)

10. Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
  • 10.3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
  • 10.4.Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Region, 2021-2031, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 10.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 10.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 10.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)

11. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
  • 11.3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
  • 11.4.Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Region, 2021-2031, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 11.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 11.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 11.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)

12. Company Profile

  • 12.1. Intercept Pharmaceuticals
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Galmed Pharmaceuticals
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Inventiva Pharma
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. AbbVie Inc.
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Galectin Therapeutics Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Madrigal Pharmaceuticals
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. NGM Biopharmaceuticals Inc.
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Novo Nordisk A/S
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Bristol Myers Squibb
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Gilead Sciences Inc.
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제